Measuring Response with FDG-PET: Methodological Aspects

被引：47
作者：
Allen-Auerbach, Martin [1 ]
Weber, Wolfgang A. [1 ]
机构：
[1] Univ Calif Los Angeles, David Geffen Sch Med, Sch Med, Ahmanson Biol Imaging Ctr,Dept Mol & Med Pharmaco, Los Angeles, CA 90095 USA
来源：
ONCOLOGIST | 2009年 / 14卷 / 04期
关键词：
Fluorodeoxyglucose; Positron emission tomography; Chemotherapy; Radiotherapy; Response; POSITRON-EMISSION-TOMOGRAPHY; STANDARDIZED UPTAKE VALUES; CELL LUNG-CANCER; METASTATIC BREAST-CANCER; EARLY METABOLIC-RESPONSE; PATHOLOGICAL RESPONSE; F-18; FLUORODEOXYGLUCOSE; ATTENUATION CORRECTION; PREOPERATIVE CHEMOTHERAPY; ESOPHAGOGASTRIC JUNCTION;
D O I：
10.1634/theoncologist.2008-0119
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The use of fluorodeoxyglucose positron emission tomography (FDG-PET) for the evaluation of tumor response to chemotherapy and radiation therapy has been studied in a number of malignancies. By imaging tumor metabolism and therapy-related changes, FDG-PET has demonstrated advantages over anatomical imaging in the assessment of treatment response. More recent investigations have indicated that FDG-PET can predict tumor response early during the course of therapy, potentially allowing for early treatment adjustments. The aim of this review is to provide oncologists with a basic knowledge of the practical aspects of PET quantification for treatment. The Oncologist 2009; 14: 369-377
引用
收藏
页码：369 / 377
页数：9
相关论文
共 83 条
[1]   Enhanced staging and all chemotherapy preoperatively in patients with potentially resectable gastric carcinoma [J].
Ajani, JA ;
Mansfield, PF ;
Lynch, PM ;
Pisters, PW ;
Feig, B ;
Dumas, P ;
Evans, DB ;
Raijman, I ;
Hargraves, K ;
Curley, S ;
Ota, DM .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (08) :2403-2411
[2]   An initial experience with FDG-PET in the imaging of residual disease after induction therapy for lung cancer [J].
Akhurst, T ;
Downey, RJ ;
Ginsberg, MS ;
Gonen, M ;
Bains, M ;
Korst, R ;
Ginsberg, RJ ;
Rusch, VW ;
Larson, SM .
ANNALS OF THORACIC SURGERY, 2002, 73 (01) :259-264
[3]  
Antoch G, 2002, J NUCL MED, V43, P1339
[4]   Prediction of response to neoadjuvant chemotherapy by sequential F-18-fluorodeoxyglucose positron emission tomography in patients with advanced-stage ovarian cancer [J].
Avril, N ;
Sassen, S ;
Schmalfeldt, B ;
Naehrig, J ;
Rutke, S ;
Weber, WA ;
Werner, M ;
Graeff, H ;
Schwaiger, M ;
Kuhn, W .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (30) :7445-7453
[5]  
Bancewicz J, 2002, LANCET, V359, P1727
[6]   Adenocarcinomas of esophagogastric junction: Multi-detector row CT to evaluate early response to neoadjuvant chemotherapy [J].
Beer, AJ ;
Wieder, HA ;
Lordick, F ;
Ott, K ;
Fischer, M ;
Becker, K ;
Stollfuss, J ;
Rummeny, EJ .
RADIOLOGY, 2006, 239 (02) :472-480
[7]   PET/CT with intravenous contrast can be used for PET attenuation correction in cancer patients [J].
Berthelsen, AK ;
Holm, S ;
Loft, A ;
Klausen, TL ;
Andersen, F ;
Hojgaard, L .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2005, 32 (10) :1167-1175
[8]  
Brücher BLDM, 2001, ANN SURG, V233, P300
[9]   FDG pet studies during treatment:: Prediction of therapy outcome in head and neck squamous cell carcinoma [J].
Brun, E ;
Kjellén, E ;
Tennvall, J ;
Ohlsson, T ;
Sandell, A ;
Perfekt, R ;
Wennerberg, J ;
Strand, SE .
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2002, 24 (02) :127-135
[10]   Objective response to chemotherapy as a potential surrogate end point of survival in metastatic breast cancer patients [J].
Bruzzi, P ;
Del Mastro, L ;
Sormani, MP ;
Bastholt, L ;
Danova, M ;
Focan, C ;
Fountzilas, G ;
Paul, J ;
Rosso, R ;
Venturini, M .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (22) :5117-5125
123456789